Dynavax Technologies | DVAX - Equity Capital And Reserves



Dynavax Technologies reported $494.16M in Equity Capital and Reserves for its fiscal quarter ending in June of 2025.


Equity Capital And Reserves Change Date
AbbVie USD 1.46B 1.86B Mar/2025
Adma Biologics USD 398.32M 49.3M Jun/2025
Amgen USD 7.43B 1.22B Jun/2025
AstraZeneca USD 44.72B 3.68B Jun/2025
Biogen USD 17.63B 655.3M Jun/2025
BioMarin Pharmaceutical USD 6.03B 233.65M Jun/2025
Bristol-Myers Squibb USD 17.49B 100M Jun/2025
Dynavax Technologies USD 494.16M 36.78M Jun/2025
Gilead Sciences USD 19.67B 596M Jun/2025
Glaxosmithkline GBP 14.35B 683M Jun/2025
Merck USD 49.06B 725M Jun/2025
Neurocrine Biosciences USD 2.69B 158.6M Jun/2025
Novartis USD 42.05B 3.6B Jun/2025
Pfizer USD 88.7B 1.64B Jun/2025
Regeneron Pharmaceuticals USD 29.94B 551.3M Jun/2025
Roche Holding CHF 36.16B 3.28B Dec/2024
Sarepta Therapeutics USD 1.36B 214.66M Jun/2025
TG Therapeutics USD 276.43M 39.14M Jun/2025
Vertex Pharmaceuticals USD 17.18B 679.1M Jun/2025